Abstract
Background: Mega trials of rhythm vs rate control could not demonstrate the usefulness of available antiarrhythmic drugs, so a more effective and safer therapy for atrial fibrillation (AF) is now required. One candidate is the so-called "upstream therapy", which refers to the blockade of upstream modifying elements (renin-angiotensin system, cathecholamines, oxidative stress etc) that contribute to the arrhythmogenic substrate. Methods and Results: The Japanese Rhythm Management Trial II for Atrial Fibrillation (J-RHYTHM II study) is a randomized comparative evaluation of an angiotensin II type 1 blocker (candesartan) and a dihydropiridine calcium blocker (amlodipine), both combined with antithrombotic therapy, as an antiarrhythmic therapy for the treatment of paroxysmal AF (PAF) associated with hypertension. To test the usefulness of this therapy, this study will reveal the recurrence rate of asymptomatic as well as symptomatic PAF during 1-year of treatment with candesartan or amlodipine, using daily transtelephonic monitoring. Conclusions: The J-RHYTHM II study will follow 400 patients with PAF and hypertension who were treated at approximately 50 sites throughout Japan, and will provide clinically important information.
| Original language | English |
|---|---|
| Pages (from-to) | 1318-1321 |
| Number of pages | 4 |
| Journal | Circulation Journal |
| Volume | 70 |
| Issue number | 10 |
| DOIs | |
| Publication status | Published - 02-10-2006 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Cardiology and Cardiovascular Medicine
Cite this
}
Randomized study of angiotensin II type 1 receptor blocker vs dihydropiridine calcium antagonist for the treatment of paroxysmal atrial fibrillation in patients with hypertension - The J-RHYTHM II study design for the investigation of upstream therapy for atrial fibrillation. / Yamashita, Takeshi; Ogawa, Satoshi; Aizawa, Yoshifusa; Atarashi, Hirotsugu; Inoue, Hiroshi; Ohe, Tohru; Okumura, Ken; Ohtsu, Hiroshi; Kato, Takao; Kamakura, Shiro; Kumagai, Koichiro; Kurachi, Yoshihisa; Kodama, Itsuo; Koretsune, Yukihiro; Saikawa, Tetsunori; Sakurai, Masayuki; Sugi, Kaoru; Nakaya, Haruaki; Hirai, Makoto; Hirayama, Atsushi; Fukatani, Masahiko; Mitamura, Hideo; Yamazaki, Tsutomu; Watanabe, Eiichi.
In: Circulation Journal, Vol. 70, No. 10, 02.10.2006, p. 1318-1321.Research output: Contribution to journal › Article
TY - JOUR
T1 - Randomized study of angiotensin II type 1 receptor blocker vs dihydropiridine calcium antagonist for the treatment of paroxysmal atrial fibrillation in patients with hypertension - The J-RHYTHM II study design for the investigation of upstream therapy for atrial fibrillation
AU - Yamashita, Takeshi
AU - Ogawa, Satoshi
AU - Aizawa, Yoshifusa
AU - Atarashi, Hirotsugu
AU - Inoue, Hiroshi
AU - Ohe, Tohru
AU - Okumura, Ken
AU - Ohtsu, Hiroshi
AU - Kato, Takao
AU - Kamakura, Shiro
AU - Kumagai, Koichiro
AU - Kurachi, Yoshihisa
AU - Kodama, Itsuo
AU - Koretsune, Yukihiro
AU - Saikawa, Tetsunori
AU - Sakurai, Masayuki
AU - Sugi, Kaoru
AU - Nakaya, Haruaki
AU - Hirai, Makoto
AU - Hirayama, Atsushi
AU - Fukatani, Masahiko
AU - Mitamura, Hideo
AU - Yamazaki, Tsutomu
AU - Watanabe, Eiichi
PY - 2006/10/2
Y1 - 2006/10/2
N2 - Background: Mega trials of rhythm vs rate control could not demonstrate the usefulness of available antiarrhythmic drugs, so a more effective and safer therapy for atrial fibrillation (AF) is now required. One candidate is the so-called "upstream therapy", which refers to the blockade of upstream modifying elements (renin-angiotensin system, cathecholamines, oxidative stress etc) that contribute to the arrhythmogenic substrate. Methods and Results: The Japanese Rhythm Management Trial II for Atrial Fibrillation (J-RHYTHM II study) is a randomized comparative evaluation of an angiotensin II type 1 blocker (candesartan) and a dihydropiridine calcium blocker (amlodipine), both combined with antithrombotic therapy, as an antiarrhythmic therapy for the treatment of paroxysmal AF (PAF) associated with hypertension. To test the usefulness of this therapy, this study will reveal the recurrence rate of asymptomatic as well as symptomatic PAF during 1-year of treatment with candesartan or amlodipine, using daily transtelephonic monitoring. Conclusions: The J-RHYTHM II study will follow 400 patients with PAF and hypertension who were treated at approximately 50 sites throughout Japan, and will provide clinically important information.
AB - Background: Mega trials of rhythm vs rate control could not demonstrate the usefulness of available antiarrhythmic drugs, so a more effective and safer therapy for atrial fibrillation (AF) is now required. One candidate is the so-called "upstream therapy", which refers to the blockade of upstream modifying elements (renin-angiotensin system, cathecholamines, oxidative stress etc) that contribute to the arrhythmogenic substrate. Methods and Results: The Japanese Rhythm Management Trial II for Atrial Fibrillation (J-RHYTHM II study) is a randomized comparative evaluation of an angiotensin II type 1 blocker (candesartan) and a dihydropiridine calcium blocker (amlodipine), both combined with antithrombotic therapy, as an antiarrhythmic therapy for the treatment of paroxysmal AF (PAF) associated with hypertension. To test the usefulness of this therapy, this study will reveal the recurrence rate of asymptomatic as well as symptomatic PAF during 1-year of treatment with candesartan or amlodipine, using daily transtelephonic monitoring. Conclusions: The J-RHYTHM II study will follow 400 patients with PAF and hypertension who were treated at approximately 50 sites throughout Japan, and will provide clinically important information.
UR - http://www.scopus.com/inward/record.url?scp=33749034218&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33749034218&partnerID=8YFLogxK
U2 - 10.1253/circj.70.1318
DO - 10.1253/circj.70.1318
M3 - Article
C2 - 16998266
AN - SCOPUS:33749034218
VL - 70
SP - 1318
EP - 1321
JO - Circulation Journal
JF - Circulation Journal
SN - 1346-9843
IS - 10
ER -